Skip to content

Advertisement

Alzheimer's Research & Therapy

What do you think about BMC? Take part in

Articles

Sort by
Previous Page Page 1 of 21 Next Page
  1. Content type: Research

    Gantenerumab is a fully human monoclonal antibody that binds aggregated amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the SCarlet RoAD trial, we assessed the efficacy and safet...

    Authors: Susanne Ostrowitzki, Robert A. Lasser, Ernest Dorflinger, Philip Scheltens, Frederik Barkhof, Tania Nikolcheva, Elizabeth Ashford, Sylvie Retout, Carsten Hofmann, Paul Delmar, Gregory Klein, Mirjana Andjelkovic, Bruno Dubois, Mercè Boada, Kaj Blennow, Luca Santarelli…

    Citation: Alzheimer's Research & Therapy 2017 9:95

    Published on:

  2. Content type: Research

    Biomarkers such as amyloid imaging are increasingly used for diagnosis in the early stages of Alzheimer’s disease. Very few studies have examined this from the perspective of the patient. To date, there is onl...

    Authors: Gwendolien Vanderschaeghe, Jolien Schaeverbeke, Rose Bruffaerts, Rik Vandenberghe and Kris Dierickx

    Citation: Alzheimer's Research & Therapy 2017 9:92

    Published on:

  3. Content type: Research

    Alzheimer’s disease (AD) is the most common type of dementia, affecting one in eight adults over 65 years of age. The majority of AD cases are sporadic, with unknown etiology, and only 5% of all patients with ...

    Authors: Anna Ochalek, Balázs Mihalik, Hasan X. Avci, Abinaya Chandrasekaran, Annamária Téglási, István Bock, Maria Lo Giudice, Zsuzsanna Táncos, Kinga Molnár, Lajos László, Jørgen E. Nielsen, Bjørn Holst, Kristine Freude, Poul Hyttel, Julianna Kobolák and András Dinnyés

    Citation: Alzheimer's Research & Therapy 2017 9:90

    Published on:

  4. Content type: Research

    Clusterin and beta-amyloid (Aβ) are involved in the pathogenesis of Alzheimer’s disease (AD). The clinical significance of plasma clusterin and Aβ in AD progression remains controversial.

    Authors: Jung-Lung Hsu, Wei-Ju Lee, Yi-Chu Liao, Shuu-Jiun Wang and Jong-Ling Fuh

    Citation: Alzheimer's Research & Therapy 2017 9:91

    Published on:

  5. Content type: Research

    Minimally invasive specific biomarkers of neurodegenerative diseases (NDs) would facilitate patient selection and disease progression monitoring. We describe the assessment of circulating brain-enriched microR...

    Authors: Kira S. Sheinerman, Jon B. Toledo, Vladimir G. Tsivinsky, David Irwin, Murray Grossman, Daniel Weintraub, Howard I. Hurtig, Alice Chen-Plotkin, David A. Wolk, Leo F. McCluskey, Lauren B. Elman, John Q. Trojanowski and Samuil R. Umansky

    Citation: Alzheimer's Research & Therapy 2017 9:89

    Published on:

  6. Content type: Research

    African Americans have been reported to have a higher prevalence of Alzheimer’s disease (AD) than Caucasians, but etiology-specific AD biomarkers have not been systematically analyzed in older African American...

    Authors: Jennifer C. Howell, Kelly D. Watts, Monica W. Parker, Junjie Wu, Alexander Kollhoff, Thomas S. Wingo, Cornelya D. Dorbin, Deqiang Qiu and William T. Hu

    Citation: Alzheimer's Research & Therapy 2017 9:88

    Published on:

  7. Content type: Commentary

    This commentary discusses the implications of disease-modifying treatments for Alzheimer’s disease which seem likely to appear in the next few years and results from a meeting of British experts in neurodegene...

    Authors: Craig W. Ritchie, Tom C. Russ, Sube Banerjee, Bob Barber, Andrew Boaden, Nick C. Fox, Clive Holmes, Jeremy D. Isaacs, Ira Leroi, Simon Lovestone, Matt Norton, John O’Brien, Jim Pearson, Richard Perry, James Pickett, Adam D. Waldman…

    Citation: Alzheimer's Research & Therapy 2017 9:85

    Published on:

  8. Content type: Research

    From earlier studies it is known that the APOE ε2/ε3/ε4 polymorphism modulates the concentrations of cerebrospinal fluid (CSF) beta-amyloid1–42 (Aβ42) in patients with cognitive decline due to Alzheimer’s disease...

    Authors: Ronald Lautner, Philip S. Insel, Tobias Skillbäck, Bob Olsson, Mikael Landén, Giovanni B. Frisoni, Sanna-Kaisa Herukka, Harald Hampel, Anders Wallin, Lennart Minthon, Oskar Hansson, Kaj Blennow, Niklas Mattsson and Henrik Zetterberg

    Citation: Alzheimer's Research & Therapy 2017 9:87

    Published on:

  9. Content type: Research

    A reliable blood-based assay is required to properly diagnose and monitor Alzheimer’s disease (AD). Many attempts have been made to develop such a diagnostic tool by measuring amyloid-β oligomers (AβOs) in the...

    Authors: Seong Soo A. An, Byoung-sub Lee, Ji Sun Yu, Kuntaek Lim, Gwang Je Kim, Ryan Lee, Shinwon Kim, Sungmin Kang, Young Ho Park, Min Jeong Wang, Young Soon Yang, Young Chul Youn and SangYun Kim

    Citation: Alzheimer's Research & Therapy 2017 9:86

    Published on:

  10. Content type: Research

    The progression of mild cognitive impairment (MCI) to Alzheimer’s disease (AD) dementia can be predicted by cognitive, neuroimaging, and cerebrospinal fluid (CSF) markers. Since most biomarkers reveal compleme...

    Authors: Lutz Frölich, Oliver Peters, Piotr Lewczuk, Oliver Gruber, Stefan J. Teipel, Hermann J. Gertz, Holger Jahn, Frank Jessen, Alexander Kurz, Christian Luckhaus, Michael Hüll, Johannes Pantel, Friedel M. Reischies, Johannes Schröder, Michael Wagner, Otto Rienhoff…

    Citation: Alzheimer's Research & Therapy 2017 9:84

    Published on:

  11. Content type: Review

    Brain lesions in Alzheimer’s disease (AD) are characterized by Aβ accumulation, neurofibrillary tangles, and synaptic and neuronal vanishing. According to the amyloid cascade hypothesis, Aβ1-42 oligomers could...

    Authors: Jacques Hugon, François Mouton-Liger, Julien Dumurgier and Claire Paquet

    Citation: Alzheimer's Research & Therapy 2017 9:83

    Published on:

  12. Content type: Review

    Gene suppression approaches have emerged over the last 20 years as a novel therapeutic approach for the treatment of neurodegenerative diseases. These include RNA interference and anti-sense oligonucleotides, ...

    Authors: Rhia Ghosh and Sarah J. Tabrizi

    Citation: Alzheimer's Research & Therapy 2017 9:82

    Published on:

  13. Content type: Research

    Research has revealed that manifest Alzheimer’s disease (AD) dementia is preceded by preclinical and prodromal phases during which pathology is accumulating but function remains intact. This understanding and ...

    Authors: Michelle M. Nuño, Daniel L. Gillen, Kulwant K. Dosanjh, Jenny Brook, David Elashoff, John M. Ringman and Joshua D. Grill

    Citation: Alzheimer's Research & Therapy 2017 9:81

    Published on:

  14. Content type: Research

    The deposition of neurotoxic amyloid-β (Aβ) peptides in plaques in the brain parenchyma and in cerebral blood vessels is considered to be a key event in Alzheimer’s disease (AD) pathogenesis. Although the pres...

    Authors: Oliver Wirths, Susanne Walter, Inga Kraus, Hans W. Klafki, Martina Stazi, Timo J. Oberstein, Jorge Ghiso, Jens Wiltfang, Thomas A. Bayer and Sascha Weggen

    Citation: Alzheimer's Research & Therapy 2017 9:80

    Published on:

  15. Content type: Research

    Tauopathies represent heterogeneous groups of neurodegenerative diseases that are characterised by abnormal deposition of the microtubule-associated protein tau. Alzheimer’s disease is the most prevalent tauop...

    Authors: Radana Karlíková, Kateřina Mičová, Lukáš Najdekr, Alžběta Gardlo, Tomáš Adam, Petra Majerová, David Friedecký and Andrej Kováč

    Citation: Alzheimer's Research & Therapy 2017 9:78

    Published on:

  16. Content type: Research

    The choice and appropriate use of animal models in drug discovery for Alzheimer’s disease (AD) is pivotal to successful clinical translation of novel therapeutics, yet true alignment of research is challenging...

    Authors: Thomas Blackmore, Soraya Meftah, Tracey Karen Murray, Peter James Craig, Anthony Blockeel, Keith Phillips, Brian Eastwood, Michael J. O’Neill, Hugh Marston, Zeshan Ahmed, Gary Gilmour and Francois Gastambide

    Citation: Alzheimer's Research & Therapy 2017 9:77

    Published on:

  17. Content type: Research

    Alzheimer’s disease (AD) progression varies substantially among patients, hindering calculation of residual total life expectancy (TLE) and its decomposition into disability-free life expectancy (DFLE) and dis...

    Authors: Eric Stallard, Bruce Kinosian and Yaakov Stern

    Citation: Alzheimer's Research & Therapy 2017 9:75

    Published on:

  18. Content type: Research

    Dysfunction of the serotonergic (5-HTergic) system has been implicated in the cognitive and behavioural symptoms of Alzheimer’s disease (AD). Accumulation of toxic amyloid-β (Aβ) species is a hallmark of AD an...

    Authors: Christian Ulrich von Linstow, Jonas Waider, Manuela Grebing, Athanasios Metaxas, Klaus Peter Lesch and Bente Finsen

    Citation: Alzheimer's Research & Therapy 2017 9:74

    Published on:

  19. Content type: Research

    Alzheimer’s disease (AD) impacts men and women differently, but the effect of sex on predementia stages is unclear. The objective of this study was to examine whether sex moderates the impact of florbetapir po...

    Authors: Jessica Z. K. Caldwell, Jody-Lynn Berg, Jeffrey L. Cummings and Sarah J. Banks

    Citation: Alzheimer's Research & Therapy 2017 9:72

    Published on:

  20. Content type: Review

    Due to the progressive aging of the population, Alzheimer’s disease (AD) is becoming a healthcare burden of epidemic proportions for which there is currently no cure. Disappointing results from clinical trials...

    Authors: Marta Crous-Bou, Carolina Minguillón, Nina Gramunt and José Luis Molinuevo

    Citation: Alzheimer's Research & Therapy 2017 9:71

    Published on:

  21. Content type: Research

    Amyloid pathology in subjects with mild cognitive impairment (MCI) is an important risk factor for progression to dementia due to Alzheimer’s disease. Predicting the onset of dementia is challenging even in th...

    Authors: Mara ten Kate, Frederik Barkhof, Pieter Jelle Visser, Charlotte E. Teunissen, Philip Scheltens, Wiesje M. van der Flier and Betty M. Tijms

    Citation: Alzheimer's Research & Therapy 2017 9:73

    Published on:

Previous Page Page 1 of 21 Next Page